Catalent, Somerset
Catalent to sell Somerset HQ
The site also serves as an oral solids development and small-scale manufacturing facility for the pharmaceutical company, which is in talks with Novo Holdings for a $16.5 billion acquisition.
Catalent to sell New Jersey facility
Catalent has agreed to sell its oral drug development and small-scale manufacturing facility in Somerset, New Jersey to private contract drug manufacturer Ardena, the companies said on Monday. Catalent provides contract manufacturing services and performs fill-finish work,
Catalent to sell Somerset oral solids facility
Catalent (NYSE:CTLT) is selling its oral solids development and small-scale manufacturing facility in Somerset, New Jersey to contract manufacturer Ardena. Financial details of the agreement, which is expected to close in early 2025,
Catalent Signs Agreement to Sell Somerset, NJ Oral Solids Facility
Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, announced today that it has entered into a definitive agreement to sell its oral solids development and small-scale manufacturing facility in Somerset,
Catalent to Sell Somerset Oral Solids Facility to Ardena
Catalent entered into a definitive agreement to sell its oral solids development and small-scale manufacturing facility in Somerset to Ardena
Catalent To Sell Oral Solids Development Facility In Somerset, NJ To Ardena
Catalent, Inc. (CTLT), a provider of advanced delivery technologies and development solutions for drugs, biologics, and consumer
FiercePharma1d
Catalent offloads New Jersey manufacturing plant, HQ to Belgian CDMO Ardena
Awaiting a potential acquisition by Novo Holdings, Catalent is giving its contract manufacturing compatriot a boost as Ardena ...
bovnews4h
Stock Shock: The Unpredictable Rise and Fall of CTLT—What’s Driving the Drama?
On Monday, Catalent Inc (CTLT) stock saw a modest uptick, ending the day at $60.65 which represents a slight increase of $0.20 or 0.33% from the prior close of $60.45. The stock opened at $60.5 and ...
Ardena Signs Agreement to Expand US Footprint with the Acquisition of Advanced Drug Product Manufacturing Facility from Catalent
Somerset facility State-of-the art facility for clinical and commercial manufacturing of oral dosage forms. Ghent, Belgium, ...
BioSpace4d
Pressure Mounts on Novo’s $16.5B Catalent Buy Amid FTC Review
Senator Elizabeth Warren told the Federal Trade Commission that the acquisition of contract manufacturer Catalent could ...
STAT5d
Warren urges FTC to probe deal that would give Novo Nordisk control of some Catalent plants
U.S. Sen. Elizabeth Warren has asked the Federal Trade Commission “closely scrutinize” a $16.5 billion deal in which Novo ...
bovnews4d
Catalent Inc (CTLT) Stock: More Strategic Than Meets the Eye
On Thursday, Catalent Inc (CTLT) stock saw a decline, ending the day at $60.71 which represents a decrease of $-0.25 or -0.41% from the prior close of $60.96. The stock opened at $60.78 and touched a ...
ophthalmologytimes4d
Melt Pharmaceuticals doses final patient in phase 3 trial of MELT-300
The phase 3 clinical trial is a randomized, double-blind, three-arm study comparing MELT-300, sublingual midazolam, and ...
STAT4d
A setback for the Denali-Sanofi partnership
Six years ago, Sanofi gave $125 million and promised over $1 billion in milestone payments to buzzy neuroscience startup ...